Novel antagonists of α4ß1 integrin and/or α4ß7 integrin of the general Formula I: or a pharmaceutically acceptable salt thereof, wherein: R1 is C3-10alkyl C3.10alkenyl, C3.10alkynyl, cycloalkyl, cycloalkyl-C1-10.alkyl, cycloalkyl-C2. 10alkenyl, cycloalkyl-C2.10alkynyl, heterocyciyl, heterocyclyl-C1-10 alkyl, heterocyclyl-C2. i0alkenyl, heterocyclyl-C2.10alkynyl, aryl, aryl-C1-10 alkyl, aryl-C2.10alkenyl, aryl-C2. 10alkynyl, heteroaryl, heteroaryl-C1-10alkyl, heteroaryl- C2.10alkenyl, or heteroaryl- C2. 10alkynyl; wherein said alkyl, alkenyl, and alkynyl groups or moieties are unsubstituted or substituted with one to foursubstituents, which may be the same or different and are independently selected from Ra; and wherein said cycloalkyl, heterocyciyl, aryl and heteroaryl groups or moieties are unsubstituted or substituted with one to four substituents, which may be the same or different and are independently selected from Rb; R2 is hydrogen, Chalky!, C0.2alkylcycloalkyl, C0-2alkylaryl or C0.2alkylheteroaryl wherein said aryl and heteroaryl groups or moieties are unsubstituted or substituted with one to four substituents, which may be the same or different and are independently selected from Ra; R3 and R4 are independently hydrogen or C1-4alkyl; R2 and R3, together with the atoms to which they are attached, may form a 4-8 membered ring; R5 is C1-6alkyl, cycioalkyl, cycloalkyl-C1-4alkyl, heterocyclyl, heterocyclyl-C1-4alkyl, aryl, aryl-C1-4alkyl, heteroaryi, or heteroaryl-C1-4alkyl; wherein said aikyl groups or moieties are unsubstituted or substituted with one to four substituents, which may be the same or different and are independently selected from Ra; and wherein said cycioalkyl, heterocyclyl, aryl and heteroaryi groups or moieties are unsubstituted or substituted with one to four substituents, which may be the same or different and are independently selected from Rb; L1 is -S-, -S(O)-, -S(0)r, -C(O)-, -C(O)O-, -C(S)-, -N(Rc)-, -CH2-, -CH2N(Rc)-, -CON(Rc)-, -CSN(Rc)-, -N(Rc)CO-, -N(Rc)CS-, -S(O)2N(Rc)- or -N(Rc)S(O)2-; L2 is a covalent bond, -O-, -S-, -S(O)-, -S(O)2-, -C(O)-, -C(O)O-, -OC(O)-, -C(S)-, -N(Rc)-, -CON(Rc)-, -OC(O)N(Rc), -CSN(Rc)-, -N(Rc)CO-, -N(Rc)C(O)O-, -N(Rc)CS-, -S(O)2N(Rc)-, -N(Rc)S(O)r, -N(Rc)CON(Rc)-, or -N(Rc)CSN(Rc)-, wherein if two Re substituents are present, these may be the same or different; WisO, S, NH,N(Rc), orNCN; X is -(CH2)naryl-, or -(CH2)nheteroaryl-; wherein said aryl and heteroaryi moieties are unsubstituted or substituted with one to foursubstituents, which may be the same or different and are independently selected from Rb; Y is monocyclic aryl, or monocyclic heteroaryi containing one or two heteroatoms selected from N, O and S, wherein said aryl and heteroaryi moieties are unsubstituted or substituted with one to foursubstituents, which may be the same or different and are independently selected from Rb; Z is -C(O)ORd, -P(O)2ORd, -S(O)2ORd, -S(O)2N(Rd)(Rd), -C(O)NH2, -C(O)N(Re)S(O)2Rd, -S(O)2N(Re)C(O)Rd, -5-tetrazolyl, or -C(O)Rd; wherein if two Rd groups are present these may be the same or different;